Vasoactive intestinal polypeptide receptor VPAC1 subtype is predominant in rat prostate membranes

Prostate

Volumn 41, Issue 1, 1999, Pages 1-6

  Juarranz, Maria G ^a   De Neef, Philippe ^a   Robberecht, Patrick ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Adenylate cyclase activity; Prostate; VIP agonist; VIP antagonist; VPAC1 receptors; VPAC2 receptors

Indexed keywords

ADENYLATE CYCLASE; GROWTH HORMONE RELEASING FACTOR DERIVATIVE; NEUROPEPTIDE; PROSTATE SPECIFIC ANTIGEN; RECEPTOR SUBTYPE; VASOACTIVE INTESTINAL POLYPEPTIDE ANTAGONIST; VASOACTIVE INTESTINAL POLYPEPTIDE DERIVATIVE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE; RAT; RECEPTOR AFFINITY; RECEPTOR BINDING; RECEPTOR DENSITY;

ADENYLATE CYCLASE; ANIMALS; BINDING, COMPETITIVE; CELL MEMBRANE; CHO CELLS; CRICETINAE; ENZYME ACTIVATION; INHIBITORY CONCENTRATION 50; KINETICS; MALE; PEPTIDE FRAGMENTS; PEPTIDES, CYCLIC; PROSTATE; RATS; RATS, WISTAR; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0032813729     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19990915)41:1<1::AID-PROS1>3.0.CO;2-A     Document Type: Article

References (33)

1. Fahrenkrug J. Vasoactive intestinal polypeptide: measurement, distribution and putative neurotransmitter function. Digestion 1979;19:149-169.
2. Ishihara T, Shigemoto R, Mori K, Takahashi K, Nagata S. Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron 1992;8:811-819.
3. 2 receptor: molecular characterization of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS Lett 1993;334:3-8.
4. Couvineau A, Rouyer-Fessard C, Darmoul D, Maoret JJ, Carrero I, Ogier-Denis E, Laburthe M. Human intestinal VIP receptor: cloning and functional expression of two cDNA encoding proteins with different N-terminal domains. Biochem Biophys Res Commun 1994;200:769-776.
5. Svoboda M, Tastenoy M, Van Rampelbergh J, Goosens JF, De Neef P, Waelbroeck M, Robberecht P. Molecular cloning and functional characterization of a human VIP receptor from SUPT1 lymphoblasts. Biochem Biophys Res Commun 1994;205: 1617-1624.
6. Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna JR, Rawlings SR, Robberecht P, Said SI, Sreedharan SP, Wank SA, Waschek JA. Nomenclature of receptors for vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP). Pharmacol Rev 1998;50:265-270.
7. Usdin TB, Bonner TI, Mezey E. Two receptors for vasoactive intestinal polypeptide with similar specifity and complementary distribution. Endocrinology 1994;135:2662-2680.
8. Vertongen P, Schiffmann SN, Gourlet P, Robberecht P. Autoradiographic visualisation of the receptor subclasses for vasoactive intestinal polypeptide (VIP) in brain. Peptides 1997;18:547-1554.
9. 2 receptor subclass. Peptides 1997;18:403-408.
10. 1 receptor agonists. Peptides 1997;18:1539-1545.
11. 1 receptor. Peptides 1997;18:1555-1560.
12. Gkonos PJ, Krongrad A, Roos BA. Neuroendocrine peptides in the prostate. Urol Res 1995;23:81-87.
13. Lange W, Unger J. Peptidergic innervation within the prostate gland and seminal vesicle. Urol Res 1990;18:337-340.
14. Tainio H. Peptidergic innervation of the human prostate, seminal vesicle and vas deferent. Acta Histochem (Jena) 1995;97:113-119.
15. Crowe R, Milner P, Lincoln J, Burnstock G. Histochemical and biochemical investigation of adrenergic, cholinergic and peptidergic innervation of the rat ventral prostate 8 weeks after streptozotocin-induced diabetes. J Auton Nerv System 1987;20:103-112.
16. Said SI. Vasoactive intestinal peptide. Biological role in health and disease. Trends Endocrinol Metab 1992;2:107-112.
17. Larsson L, Ottensen B, Fahrenkrug J, Fahrenkrug L. Vasoactive intastinal polypeptide (VIP) in the male genitourinary tract. Concentration and motor effect. Invest Urol 1981;19:211-213.
18. Guijarro LG, Juarranz MG, Marinero MJ, Pajuelo L, Carmena MJ, Prieto JC. Modulation of cyclic AMP and inositol phosphate production in rat prostatic cultures by VIP/PACAP, ATP and carbachol. Role in prostatic proliferation. Ann NY Acad Sci 1996;805:723-728.
19. Hoosein NM, Logothetis CJ, Chung IWK. Differential effects of peptide hormones, bombesin, vasoactive intestinal polypeptide and somatostatin analogue RC-160 on the invasive capacity of human prostatic carcinoma cells. J Urol 1993;149:1209-1213.
20. Gkonos PJ, Ashby MH, Andrade AA. Vasoactive intestinal peptide stimulates prostate-specific antigen secretion by LNCaP prostate cancer cells. Regul Pept 1996;65:153-157.
21. Juarranz MG, Guijarro LG, Bajo A, Carmena MJ, Prieto JC. Ontogeny of vasoactive intestinal peptide receptors in rat ventral prostate. Gen Pharmacol 1994;25:509-514.
22. Prieto JC, Carmena MJ. Receptors for vasoactive intestinal peptide on isolated epithelial cells of rat ventral prostate. Biochem Biophys Acta 1983;763:408-411.
23. Solano RM, Carmena MJ, Carrero I, Cavallaro S, Román F, Hueso C, Travali S, López-Fraile N, Guijarro LG, Prieto JC. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate. Endocrinology 1996;137:2815-2822.
24. Robberecht P, Gourlet P, De Neef P, Woussen-Colle MC, Vandermeers-Piret MC, Vandermeers A, Christophe J. Receptor occupancy and adenylate cyclase activation in AR 4-2J rat pancreatic acinar cell membranes by analogs of pituitary adenylate cyclase-activating peptide amino-terminally shorted or modified at position 1, 2, 3, 20 or 21. Mol Pharmacol 1992;42:347-355.
25. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurement with the Polin phenol reagent. J Biol Chem 1951;193: 265-275.
26. Munson P, Rodbard D. LIGAND: a versatile computerized approach for characterization of ligand-binding sites. Anal Biochem 1980;107:220-239.
27. Ciccarelli E, Vilardaga JP, De Neef P, Di Paolo E, Waelbroeck M, Bollen A, Robberecht P. Properties of the VIP-PACAP type-II receptor stably expressed in CHO cells. Regul Pept 1994;54:397-407.
28. Salomon Y, Londos C, Rodbell M. A highly sensitive adenylate cyclase assay. Anal Biochem 1974;58:541-548.
29. Carmena MJ, Recio MN, Prieto JC. Influence of castration and testosterone treatment on the vasoactive intestinal peptide receptor/effector system in rat prostatic epithelial cells. Biochim Biophys Acta 1988;969:86-90.
30. Carmena MJ, Clemente C, Guijarro LG, Prieto JC. The effect of streptozotocin diabetes on the vasoactive intestinal peptide receptor:effector system in membranes from rat ventral prostate. Endocrinology 1992;131:1993-1998.
31. Gkonos PJ, Lokeshwar BL, Balkan W, Roos B. Neuroendocrine peptides stimulate adenyl cyclase in normal and malignant prostate cells. Regul Pept 1995;59:43-51.
32. 1) receptors stimulate inositol phosphate synthesis in transfected CHO cells through interaction with different G proteins. Biochim Biophys Acta 1997;1357:249-255.
33. Simonneaux V, Kienlen-Campard P, Loeffler JP, Basille M, Gonzalez BJ, Vaudry H, Robberecht P, Pévet P. Pharmacological, molecular and functional characterization of vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptors in rat pineal gland. Neuroscience 1998; 85:887-896.